Tobi 300 Mg/5 Ml 300 mg/5 ml Clear slightly yellow solution
PDF Leaflet Revision Date: 14 November 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Long-term management of chronic pulmonary colonisation by Pseudomonas aeruginosa in cystic fibrosis patients aged 6 years and older.
Dosage (summary)
One ampoule (300 mg) twice daily for 28 days, followed by a 28-day rest period.
Special Populations
- Renal impairment
- Auditory dysfunction
- Neuromuscular disorders
Pregnancy & Breastfeeding
Not recommended during pregnancy or lactation due to potential harm to the fetus and infants.
Key Drug Interactions
- Nephrotoxic drugs
- Ototoxic drugs
- Diuretics
Contraindications
- Hypersensitivity to aminoglycosides
- Pregnancy
- Lactation
Common side effects
- Cough
- Pharyngitis
- Dyspnoea
- Tinnitus
- Dysphonia
Counselling Points
- Inhale using a nebuliser
- Monitor for signs of bronchospasm
- Avoid mixing with other medications in nebuliser
Serious warnings
- Risk of nephrotoxicity
- Risk of ototoxicity
- Bronchospasm
Important Disclaimer
The Tobi 300 Mg/5 Ml 300 mg/5 ml Clear slightly yellow solution professional information leaflet below is the property of Viatris South Africa (Pty)Ltd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
